We are live on ! Find out more
ASBP

Aspire Biopharma
ASBP

57 hedge funds and large institutions have $268M invested in Aspire Biopharma in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 10 increasing their positions, 11 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 7

4% more funds holding

Funds holding: 55 → 57 (+2)

1% more capital invested

Capital invested by funds: $265M → $268M (+$3.7M)

0% less ownership

Funds ownership: 0.07% → 0.07% (-0%)

9% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 11

Holders
57
Holders Change
+2
Holders Change %
+3.64%
% of All Funds
0.91%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
10
Reduced
11
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$8.54M
2
WCMNY
Westchester Capital Management (New York)
New York
+$7.36M
3
FTCM
First Trust Capital Management
Illinois
+$6.13M
4
MC
Meteora Capital
Florida
+$4.03M
5
AC
Aristeia Capital
Connecticut
+$3.86M

Top Sellers

Rank Fund Capital Flow
1
HCM
Highbridge Capital Management
New York
-$14.4M
2
Millennium Management
Millennium Management
New York
-$6.5M
3
TCA
Taconic Capital Advisors
New York
-$6.19M
4
Verition Fund Management
Verition Fund Management
Connecticut
-$3.05M
5
SC
Sculptor Capital
New York
-$2.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
Nomura Holdings
26
Nomura Holdings
Japan
$3.15M – – –
SCM
27
Shaolin Capital Management
Florida
$3.15M – – –
CC
28
Centiva Capital
New York
$2.64M +$2.63M +210 New
LP
29
LMR Partners
United Kingdom
$2.63M – – –
WA
30
Whitebox Advisors
Minnesota
$2.63M – – –
CIM
31
Cowen Investment Management
New York
$2.63M +$2.6M +208 New
UOC
32
UBS O'Connor
Illinois
$2.38M +$2.38M +190 New
BFM
33
Boothbay Fund Management
New York
$2.2M +$2.19M +175 New
WP
34
Woodline Partners
California
$2.1M – – –
Hudson Bay Capital Management
35
Hudson Bay Capital Management
Connecticut
$2.1M – – –
PAMP
36
Polar Asset Management Partners
Ontario, Canada
$1.84M – – –
Marshall Wace
37
Marshall Wace
United Kingdom
$1.61M -$2.6M -208 -62%
CCM
38
CAAS Capital Management
New York
$1.57M – – –
PMAM
39
Picton Mahoney Asset Management
Ontario, Canada
$1.57M – – –
SFM
40
Spartan Fund Management
Canada
$1.23M +$1.23M +98 New
WRBC
41
W.R. Berkley Corp
Connecticut
$1.12M +$1.11M +89 New
BI
42
Bulldog Investors
New Jersey
$1.08M +$875K +70 +438%
OCM
43
Oaktree Capital Management
California
$1.05M – – –
CCM
44
Context Capital Management
California
$1.05M – – –
ACM
45
Atalaya Capital Management
New York
$1.05M – – –
Citigroup
46
Citigroup
New York
$935K -$125K -10 -12%
KKRC
47
Kohlberg Kravis Roberts & Co
New York
$788K – – –
AC
48
Athos Capital
Hong Kong
$525K – – –
MTCM
49
Mint Tower Capital Management
Netherlands
$525K – – –
OAC
50
OMERS Administration Corp
Ontario, Canada
$524K – – –
1
2
3

ASBP Hedge Fund Activity: Q1 2023 in Review

57 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma (ASBP) for Q1 2023, worth a combined $268M — up 1.4% from $265M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new ASBP positions and 7 closed out — a net gain of 3 holders — while 10 added to existing stakes and 11 trimmed.

The largest buyer was D.E. Shaw & Co, adding an estimated $8.54M. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $14.4M sold.

  • 57 institutional investors held Aspire Biopharma (ASBP) as of Q1 2023, up from 55 in Q4 2022.
  • Funds reported $268M of Aspire Biopharma stock for Q1 2023, up 1.4% quarter-over-quarter.
  • 10 funds opened new Aspire Biopharma positions in Q1 2023 and 7 closed out, a net change of +3 holders.
  • The largest Aspire Biopharma buyer in Q1 2023 was D.E. Shaw & Co, an estimated $8.54M added.
  • The largest Aspire Biopharma seller in Q1 2023 was Highbridge Capital Management, an estimated $14.4M sold.

Based on aggregated 13F filings for Q1 2023.